What are the comparative outcomes of DPP-4 inhibitors versus SGLT-2 inhibitors in treating type 2 diabetes across various countries in the UK?
Fuente:
Zenodo
Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Published: |
Zenodo
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901595488256000 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | SGLT-2 inhibitors demonstrate better cardiovascular and renal outcomes compared to DPP-4 inhibitors in treating type 2 diabetes, with potential additional benefits in weight and blood pressure control. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17690567 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | What are the comparative outcomes of DPP-4 inhibitors versus SGLT-2 inhibitors in treating type 2 diabetes across various countries in the UK? Tripdatabase comparative outcomes dpp inhibitors versus sglt treating type diabetes across various countries SGLT-2 inhibitors demonstrate better cardiovascular and renal outcomes compared to DPP-4 inhibitors in treating type 2 diabetes, with potential additional benefits in weight and blood pressure control. |
| title | What are the comparative outcomes of DPP-4 inhibitors versus SGLT-2 inhibitors in treating type 2 diabetes across various countries in the UK? |
| topic | comparative outcomes dpp inhibitors versus sglt treating type diabetes across various countries |
| url | https://doi.org/10.5281/zenodo.17690567 |